AC
MYOV

Aristides Capital’s Myovant Sciences Ltd. MYOV Stock Holding History

Aristides Capital’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-67,000
Closed -$1.38M – 128
2020
Q2 		$1.38M Buy
+67,000
New +$911K 1.04% 21

Other funds holding MYOV

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Aristides Capital's MYOV Position: Q3 2020 in Review

Aristides Capital sold out of Myovant Sciences Ltd. (MYOV) in Q3 2020, closing a stake of 67,000 shares — an estimated $1.38M sold.

Aristides Capital first reported a position in MYOV in Q2 2020 and held it in 1 quarter. The position peaked at $1.38M in Q2 2020. 102 funds tracked by Wall St. Rank hold MYOV as of Q3 2020.

  • Aristides Capital reported no remaining Myovant Sciences Ltd. position as of Q3 2020 after selling out during the quarter.
  • Aristides Capital sold 67,000 Myovant Sciences Ltd. shares in Q3 2020, an estimated $1.38M.
  • Aristides Capital first reported a position in Myovant Sciences Ltd. in Q2 2020 and held it in 1 quarter.
  • Aristides Capital's Myovant Sciences Ltd. position peaked at $1.38M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q3 2020.

Based on Aristides Capital's 13F filing for Q3 2020, filed 12 Nov 2020.